Vulvovaginal Health in Older Women: Clinical Insights and Evidence-Based Management

Abstract

Vulvovaginal health in older women represents a significant yet often underappreciated aspect of geriatric and gynecological care. Aging-associated physiological changes, comorbidities, and polypharmacy can predispose this population to a spectrum of vulvovaginal disorders, most commonly genitourinary syndrome of menopause (GSM), vulvovaginal atrophy (VVA), infections, and neoplasia. This review synthesizes epidemiological data, elucidates underlying pathophysiological mechanisms, highlights risk factors, and details clinical features pertinent to older women. Evidence-based diagnostic approaches, current standards of treatment, emerging therapies, and guideline-driven recommendations are discussed, with a focus on improving patient outcomes and quality of life. Clinically relevant insights and practical management strategies are provided for healthcare professionals caring for this demographic.

Introduction

The demographic shift toward an aging population has accentuated the need for heightened clinical awareness of vulvovaginal health in older women. Postmenopausal women frequently experience vulvovaginal symptoms, yet these concerns remain underreported and undertreated due to stigma, lack of awareness, or misconceptions regarding normal aging. Vulvovaginal disorders can profoundly impact physical, sexual, and psychological well-being, underscoring the necessity for clinicians to recognize, evaluate, and manage these conditions in a comprehensive manner. This article provides an in-depth scientific review tailored for healthcare professionals, integrating recent evidence and expert consensus to inform optimal clinical practice.

Epidemiology / Disease Burden

Vulvovaginal disorders are highly prevalent among older women, with up to 50% of postmenopausal women reporting symptoms related to vulvovaginal atrophy or GSM. The true prevalence may be underestimated, as many women do not seek medical attention. Vulvovaginal candidiasis, lichen sclerosus, lichen planus, and vulvar neoplasia are also more common in this age group. The global rise in life expectancy further increases the clinical burden, with implications for primary care, gynecology, urology, and sexual medicine.

Pathophysiology

The primary pathophysiological driver of vulvovaginal changes in older women is the decline in circulating estrogen following menopause. Estrogen deficiency leads to thinning of the vulvovaginal epithelium, reduced collagen and elastin, decreased vascularity, and diminished secretions. Altered vaginal microbiota, with decreased lactobacilli and increased pH, predisposes to infections and inflammation. Chronic systemic diseases, such as diabetes and autoimmune conditions, may further exacerbate mucosal vulnerability. Neuroendocrine and immunological changes also contribute to the susceptibility and severity of vulvovaginal disorders in this population.

Risk Factors

Major risk factors for vulvovaginal disorders in older women include advancing age, menopause, and hypoestrogenism. Additional contributing factors are diabetes mellitus, obesity, immunosuppression, polypharmacy (especially with anticholinergic or cytotoxic drugs), prior pelvic irradiation, smoking, poor hygiene, and a history of gynecological surgery. Sexual inactivity can further exacerbate symptoms by decreasing vaginal elasticity and lubrication.

Clinical Features

Patients may present with vulvar or vaginal dryness, pruritus, burning, pain, dysuria, dyspareunia, or abnormal discharge. On examination, findings may include pale, thin, or friable vaginal mucosa, loss of rugae, decreased elasticity, introital narrowing, and loss of labial fullness. Secondary infections (e.g., candidiasis, bacterial vaginosis), dermatoses (e.g., lichen sclerosus), and neoplastic changes should be considered in the differential diagnosis. Psychosexual distress and impaired quality of life are frequent but often underrecognized consequences.

Diagnosis

Diagnosis is primarily clinical, based on history and physical examination. A thorough gynecological assessment is essential, including visualization of the vulva and vagina, pH testing, and, when indicated, microbiological cultures or cytology. Biopsy is warranted for atypical lesions, persistent symptoms, or suspicion of neoplasia. Symptom questionnaires and quality of life scales may aid in assessment and monitoring of disease burden.

Treatment & Management

First-line management includes patient education, reassurance, and non-hormonal therapies such as vaginal lubricants and moisturizers. Local estrogen therapy (vaginal creams, tablets, or rings) is the gold standard for GSM and VVA, with robust evidence supporting efficacy and safety, especially in the absence of contraindications to estrogen. For women with a history of hormone-dependent malignancy, non-hormonal alternatives or consultation with an oncologist is advised. Topical corticosteroids are indicated for inflammatory dermatoses (e.g., lichen sclerosus). Addressing modifiable risk factors, optimizing glycemic control, and reviewing medications are integral to management. Pelvic floor physical therapy and sexual counseling may further enhance outcomes.

Recent Advances / Emerging Therapies

Novel therapies under investigation include selective estrogen receptor modulators (SERMs), vaginal dehydroepiandrosterone (DHEA), and laser-based energy devices (e.g., CO2 laser, Er:YAG laser) for refractory GSM. Preliminary studies suggest these modalities may improve mucosal health and alleviate symptoms, though long-term safety and efficacy data are still evolving. Probiotic interventions targeting vaginal microbiota restoration, as well as regenerative medicine approaches, represent promising future directions.

Guideline Recommendations

Major guidelines from the North American Menopause Society (NAMS), International Society for the Study of Women\'s Sexual Health (ISSWSH), and American College of Obstetricians and Gynecologists (ACOG) advocate for individualized, patient-centered care. Local estrogen remains the preferred therapy for moderate to severe GSM in the absence of contraindications. Regular follow-up, monitoring for adverse effects, and interdisciplinary collaboration are emphasized. Non-hormonal modalities should be prioritized in women with contraindications to estrogen therapy, and all patients should be counseled on the chronic, relapsing nature of vulvovaginal disorders.

Conclusion

Vulvovaginal health in older women is a multidimensional clinical challenge requiring proactive identification, evidence-based management, and compassionate care. Healthcare professionals must maintain a high index of suspicion, employ guideline-driven diagnostic and therapeutic strategies, and engage in shared decision-making to optimize outcomes. Ongoing research and emerging therapies promise to further enhance the quality of life for this expanding patient population.